NVCT: Taking Half Off the Table

The rules said buy. The rules now say trim. Here's what the charts are telling us next.

Nuvectis Pharma (NVCT) was added to the model on January 5 at $8.50 and again on January 26 at $8.55, both entries timed to a weekly chart that was carving out a classic Stage 1 base. The thesis was straightforward: accumulation was building, the 30-week moving average was beginning to turn, and the Smart Money Score was signaling institutional interest…